Examinando por Materia "Isoniazida"

Mostrando 1 - 3 de 3

Acceso abierto
Effectiveness of isoniazid in preventing tuberculosis in patients with the human immunodeficiency virus
(Universidad Privada Norbert Wiener, 2020-01-05) Soto Huaccanqui, Maria Marlene; Meneses Canchari, Yda Marlene; Pérez Siguas, Rosa Eva
Objective: Systematize the evidence on the effectiveness of isoniazid in preventing tuberculosis in patients with HIV. Methodology: Systematic Review is a research design that allows us to collect and synthesize the best scientific evidence regarding a study topic. Of the studies, 6 are systematic reviews and 7 are cohort reviews. Results: We found 13 relevant studies. 90% (12) report that IPT is effective and they are from the United States, England, Tanzania, Australia and Brazil; while 10% (1) of the United States report that it is not effective in preventing tuberculosis in patients with HIV. Within these studies it was also found that the administration of isoniazid in children is 90% effective, if isoniazid is administered for 36 months compared to 6 months it is much more beneficial in patients with HIV, 6 months of isoniazid in patients with HIV reduces the risk of tuberculosis during the 7 years of follow-up, one of the reasons why a patient stops taking isionazid is the liver effects and the lack of follow-up for the IPT. Conclusions: It is concluded that the majority reports that the use of isonicide is effective in preventing tuberculosis in patients living with HIV; also that chemoprophylaxis with isionazide is important because it helps us reduce cases of tuberculosis in patients living with HIV; Therefore, it also reduces HIV/TBC mortality cases.
Acceso abierto
Effectiveness of isoniazid therapy compared to other therapies in treating latent tuberculosis infection
(Universidad Privada Norbert Wiener, 2019-12-14) Torres Hilario, Zenovia Elena; Sánchez Parinango, Eva María; Pérez Siguas, Rosa Eva
Objective: Systematize the evidence on the effectiveness of Isoniazid therapy in comparison with other therapies for the treatment of latent tuberculosis infection. Material and Methods: It is a systematic review, the articles were subjected to a critical review of the literature, using the Grade evaluation system, thus recognizing the degree of evidence, these studies were found in the databases: PubMed, Science direct, Cochrane , Epistemonikos. Of the 10 articles found, 40% (n= 4/10) are systematic reviews, 10% (n=1/10) are meta-analyses, 30% (n= 3/10) are randomized controlled trials and 20 % (n= 2/10) are a cohort study. Furthermore, these articles come from the USA (60%), followed by Canada (20%), then Australia (10%) and Spain (10%). Results: It was found that 100% (n=10/10) indicate that isoniazid preventive therapy for 6 months is as effective as other therapies for the treatment of infection with latent tuberculosis, however, all other therapies for being shorter showed greater adherence and fewer adverse effects compared to 6 months of isoniazid. Conclusion: The majority of the articles reviewed (10/10) report that isoniazid preventive therapy for 6 months is as effective as other therapies for the treatment of infection with latent tuberculosis, however, the other shorter therapies show greater adherence and fewer adverse effects.
Acceso abierto
Incidencia de la tuberculosis multidrogorresistente detectado por test GeneXpert en pacientes atendidos en el programa P.C.T del Hospital San Juan de Lurigancho, Lima - Perú 2023
(Universidad Privada Norbert Wiener, 2025-03-17) Meléndez Sudario, Carmen Rosa; Najarro Soto, Richie Allison
La tuberculosis es una enfermedad bacteriana comúnmente asociada con la infección de los pulmones, causada por Mycobacterium tuberculosis. Objetivo Determinar la incidencia de la tuberculosis multidrogo resistente detectado con el test GenExpert en pacientes atendidos en el programa P.C.T del “Hospital San Juan de Lurigancho”, Lima – Perú 2023. Material y método: Se realizó un estudio hipotético deductivo. Resultados De los 381 pacientes evaluados, el 14.2% tuvo menos de 18 años, el 22.6% de 19 a 26 años, el 44.9% de 27 a 59 años y el 18.4% más de 60 años. El 61.2% fue de sexo masculino mientras que el 38.8% de sexo femenino. El 5.24% de las muestras fue resistente a la Isoanazida. El 3.41% de las muestras fue resistente a la Rifampicina. La resistencia múltiple se presentó en el 8.1% de las muestras y la monoresistencia en el 8.6% de las muestras, no presenta resistencia el 83.2% de las muestras de esputo. Conclusión: Implementar estrategias que aseguren el acceso universal y oportuno al test GeneXpert para la detección de tuberculosis resistente, priorizando a los pacientes atendidos en el programa PCT. Además, establecer un sistema de monitoreo continuo para identificar y registrar casos de resistencia a la Isoniazida y la Rifampicina, lo que permitirá una respuesta más eficiente y focalizada.